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AutoimmunityPhospholipid scramblase activity is involved in the collapse of phospholipid (PL) asymmetry at the
plasma membrane leading to externalization of phosphatidylserine. This activity is crucial for
initiation of the blood coagulation cascade and for recognition/elimination of apoptotic cells by
macrophages. Efforts to identify gene products associated with this activity led to the characteriza-
tion of PL scramblase (PLSCR) and XKR family members which contribute to phosphatidylserine
exposure in response to apoptotic stimuli. Meanwhile, TMEM16 family members were identiﬁed
to externalize phosphatidylserine in response to elevated calcium in Scott syndrome platelets,
which is critical for activation of the coagulation cascade. Herein, we report their mechanisms of
gene regulation, molecular functions independent of their scrambling activity, and their potential
roles in pathogenic conditions.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction asymmetrically between the inner and outer leaﬂets of the plasmaPhospholipids are essential components of mammalian cell
membranes [1]. Speciﬁcally, phospholipids are distributedmembrane [1]. Phosphatidylserine (PS), one of the four major
phospholipids in the plasma membrane, is located in the inner
leaﬂet along with phosphatidylethanolamine (PE) and phosphati-
dylinositol (PI), whereas sphingomyelin (SM) and phosphatidylcho-
line (PC) are enriched in the outer leaﬂet [1]. This asymmetrical
distribution of phospholipids ismaintained by speciﬁc proteins that
regulate the translocation of these phospholipids [1,2]. However,
this distribution collapses in response to two major cellular events:
blood coagulation and apoptosis. These events involve phospholipid
‘‘scrambling’’ between the inner and outer leaﬂets of the plasma
membrane [1,2]. Transbilayer lipid motion seems to be mediated
by distinct molecules [3], including ﬂippases and ﬂoppases, which
maintainmembrane asymmetry via translocation of selective lipids
in an ATP-dependent manner, as well as scramblases. Whereas
ﬂippases and ﬂoppases move phospholipids to the inner and outer
leaﬂet, respectively, scramblases mediate transbilayer movement
in a non-selective and energy-independent mechanism.
Injuries that lead to activation of the blood coagulation pathway
involve PS externalization in platelets, allowing for interactions of
this phospholipid with coagulation factors, and thereby stimulating
production of thrombin and, consequently, blood clotting [4]. In
apoptotic cells, scramblase activity disrupts phospholipid asymme-
try resulting in PS externalization [4]. PS exposure provides a signal
for recruitment ofmacrophages to bind to and engulf apoptotic cells
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phospholipid scramblase activity [2,5,6]. Thus, the regulation of
the activities of these molecules is essential for regulating plasma
membrane phospholipid asymmetry. As described in this review,
the speciﬁc proteins that are capable of PS externalization at the
plasma membrane include PLSCR, TMEM16 (also referred to as
anoctamin (ANO)), and the XKR family members.
In red blood cells (RBC), PS externalization is not only important
for ‘‘eryptosis’’, a form of programmed cell death activated by
calcium (and required for RBC clearance) [7], but is also critical
for the process of blood coagulation [2]. For example, the common
environmental toxicants, lead and mercury, elevate scramblase
and reduce ﬂippase activities to promote PS externalization in
RBCs and initiate coagulation events [8].
Interestingly, G-protein-coupled receptors (such as Rhodopsin,
b2-adrenergic, Adenosine A2A receptors) are associated with
increased phospholipid scramblase activity, speciﬁcally at the ER
membrane [9]. For the purpose of this review, we focus on the
plasma membrane-described phospholipid scramblases. A detailed
discussion of the regulation and molecular functions of these
phospholipid scramblases, as well as their potential roles in disease
are henceforth described below (See Figs. 1 and 2).
2. Phospholipid scramblase gene products
2.1. Initial identiﬁcation of human phospholipid scramblase genes
The molecules that elicit scramblase activity had remained
unidentiﬁed until 1996, when Basse and colleagues reported the
puriﬁcation of a type II transmembrane protein from erythrocytes
[10]; when reconstituted into liposomes, this 37 kDa protein could
mediate calcium-dependent redistribution of membrane phospho-
lipids leading to PS externalization [10]. The cDNA encoding this
protein was isolated via a plaque hybridization technique, and
the gene was named PLSCR1 [11]. PLSCR1 is expressed ubiquitously
in multiple cell lines including erythrocytes and blood platelets
[11]; these cells were associated with increased phospholipid
scramblase activity in the presence of Ca+2 [11]. In 2000, Wiedmer
and colleagues reported the cloning of the human PLSCR1 gene
from a human genomic bacterial artiﬁcial chromosome (BAC)
library and estimated the size of its gene to be 29.7 Kb, encompass-
ing 9 exonic regions [12]. Three additional cDNAs with high homol-
ogy to PLSCR1 (which encodes for a 318 aa protein) were cloned by
a PCR-based approach utilizing a cDNA library, namely PLSCR2
(which encodes for a 297 aa protein), PLSCR3 (which encodes for
a 295 aa protein) and PLSCR4 (which encodes for a 329 aa protein)Phospholipid Scra
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Fig. 1. Identity of Phospholipid Scramblases: a schematic showing the responsible gene
externalizing PS in response to cellular injury/activation (i.e. blood coagulation), (2) XKR8
externalizing PS in response to apoptotic stimuli, and (4) PLSCR3 involved in movemen[12]. Another PLSCR family member, named PLSCR5 (encoding for a
271 aa protein), was identiﬁed as a ﬁfth member of the PLSCR
family (http://www.genecards.org).
However, following this initial identiﬁcation of PLSCR proteins
as the molecules mediating phospholipid scramblase activity,
members of the TMEM16 (i.e. TMEM16F and others) and XKR
(i.e. XKR8 and others) family were also identiﬁed and reported to
be involved in mediating scramblase activity [13,14].
2.2. Gene location and protein structure of human phospholipid
scramblases
2.2.1. PLSCR family members
With the exception of PLSCR3, all PLSCR family genes are clus-
tered on the q arm of chromosome 3, speciﬁcally at the 3q23/
3q24 loci (https://genome.ucsc.edu/, December 2013). Table 1A
summarizes the genetic locations and gene sizes of all the PLSCR
family members. The PLSCR1 gene is composed of 9 exons with
the coding region beginning at exon 2 and ending at exon 9.
Interestingly, an ortholog of human PLSCR1 exists in Caenorhabditis
elegans, namely scrm1, and is involved in PS externalization in
apoptotic germ cells [15,16]. In addition, additional orthologs were
identiﬁed in Drosophila melanogaster,Mus musculus, Xenopus laevis,
and Danio rerio [17].
Although various alternate splice forms of PLSCR1 have been
predicted (http://www.genecards.org), only three alternative
forms have been identiﬁed experimentally [18], and their func-
tional roles remain to be investigated. All PLSCR family members,
with the exception of PLSCR2, possess a proline-rich N-terminal
region containing PxxP and PPxY domains, a cysteine-rich region,
a conserved calcium ion binding domain (EF-hand-like), and a
putative transmembrane region enriched in hydrophobic amino
acids. In addition, PLSCR1 contains a nuclear localization signal
(NLS) and a DNA binding domain that are essential for its nuclear
localization and associated nuclear function [19–24]. Although
the NLS domain seems to be conserved in the other family
members, it has only thus far been tested in PLSCR4 (minimal
NLS domain) [25]. Further, the DNA-binding activity in the other
isoforms has yet to be assessed.
PLSCR1 has been proposed to be a type II transmembrane pro-
tein that is tail-anchored to the plasmamembrane at its C-terminal
end [26]. Although recent homology modelling studies for PLSCR1
predicted that its transmembrane domain may not be inserted into
membranes [27], ﬂuorescence quenching studies and membrane
binding assay studies suggest that the transmembrane domain is
inserted into the lipid bilayer and plays an important anchoringPLSCR1 
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products that contribute to scramblase activity including (1) TMEM16F involved in
involved in externalizing PS in response to apoptotic stimuli, (3) PLSCR1 involved in
t of cardiolipin in the mitochondrial compartment important in mitophagy.
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Fig. 2. Phospholipid scramblases in disease: a schematic showing the diseases associated with the phospholipid scramblase members of the (1) TMEM16 family, (2) XKR
family and (3) PLSCR family.
Table 1
Chromosomal location of phospholipid scramblases.
Gene Chromosomal location Size
A
PLSCR1 chr3:146,515,180-146,544,841 29,662 bp
PLSCR2 chr3:146,433,288-146,469,301 36,014 bp
PLSCR3 chr17:7,389,728-7,394,843 5116 bp
PLSCR4 chr3:146,192,336-146,251,179 58,844 bp
PLSCR5 chr3:146,576,608-146,606,216 20,379 bp
B
TMEM16A chr11:70,085,414-70,163,577 78,164 bp
TMEM16B chr12:5,562,651-5,946,232 383,582 bp
TMEM16C chr11:26,332,131-26,663,289 331,159 bp
TMEM16D chr12:100,794,596-101,128,641 334,046 bp
TMEM16E chr11:22,193,176-22,283,367 90,192 bp
TMEM16F chr12:45,215,987-45,432,351 216,365 bp
TMEM16G chr2:241,188,509-241,196,165 7657 bp
TMEM16H chr19:17,323,223-17,334,829 11,607 bp
TMEM16J chr11:417,930-442,011 24,082 bp
TMEM16K chr3:43,366,326-43,622,068 255,743 bp
C
XKR1 chrX:37,685,880-37,732,130 46,251 bp
XKR2 chrX:100,913,442-100,928,909 15,468 bp
XKR3 chr22:16,783,416-16,821,694 38,279 bp
XKR4 chr8:55,102,457-55,526,151 423,695 bp
XKR5 chr8:6,808,520-6,835,644 27,125 bp
XKR6 chr8:10,896,146-11,201,366 305,221 bp
XKR7 chr20:31,968,002-31,998,453 30,452 bp
XKR8 chr1: 27,959,993-27,968,093 8101 bp
XKR9 chr8:70,669,365-70,735,942 66,578 bp
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C-terminus of PLSCR1 is predicted to exist within the transmem-
brane and extracellular domain of PLSCR1 [29]. The cytoplasmic
domain of PLSCR1 may also associate with the lipid bilayer when
the transmembrane region is deleted; this ﬁnding implicates a role
for the cytosolic region in membrane anchoring [30].
2.2.2. TMEM16 family members
There are 10 TMEM16 family members and their genetic loca-
tions and gene sizes are summarized in Table 1B. Splice variants
for TMEM16A and TMEM16B, as well as for TMEM16F have been
identiﬁed [31]. Thus far, two C. elegans orthologs for TMEM16 have
been identiﬁed: ANOH-1 and ANOH-2 which may be involved in
sensory signaling [32]. Additionally, orthologs have been identiﬁedin D. melanogaster [33],M. musculus [34], Aspergillus fumigatus [35],
and Nectria haematococca [36].
TMEM16F, initially identiﬁed to be associated with phospho-
lipid scramblase activity [14], consists of 20 exons and encodes a
protein of 910 aa that contains 8 transmembrane domains [37].
Its N-terminal region (1–95 aa) and its C-terminal region (842–
910 aa) are required for its plasma membrane localization [38].
Mutational analyses of the putative pore-loop region between
the 5th and 6th transmembrane helices of TMEM16 family
members indicate that this region is essential for the chloride
channel (TMEM16A) and phospholipid scramblase (TMEM16F)
activities [38]. Interestingly, TMEM16A can form homo- as well
as hetero-oligomers with other TMEM16 family members [39].
Recently, the X-ray crystal structure of nhTMEM16 (N. haematococ-
ca), reveals a hydrophilic cavity that traverses the membrane and
contains a conserved calcium binding site embedded in the
hydrophobic membrane core [36].
2.2.3. XKR family members
There are 9 human XKR family members and 8 XKR murine
family members. The genomic locations and gene sizes of the
human XKR family members are summarized in Table 1C. The
orthologs of XKR8 in C. elegans (CED-8) and M. musculus (mXKR8)
also promote PS externalization [13,40].
XKR8, initially identiﬁed to be associated with phospholipid
scramblase activity [13], contains 3 exons, with the translation ini-
tiation site located within exon 1 (http://useast.ensembl.org/). The
three exons of XKR8 encode a 395 aa protein that contains 6 trans-
membrane segments. Both the N and C-termini are cytoplasmic in
orientation [13]. XKR8 contains a caspase-3 binding site that, when
mutated, abolishes its PS externalization ability [13,40,41].
3. Expression, regulation, and localization of phospholipid
scramblases
3.1. Expression and transcriptional regulation
3.1.1. PLSCR family
Northern blot analyses of human tissues show ubiquitous
expression of PLSCR1, PLSCR3, and PLSCR4 isoforms in multiple
tissues tested, whereas PLSCR2 expression seems to be restricted
to testis [12]. On the basis of their expression pattern, PLSCR family
members may play a role in development of embryos/neonates, as
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the endometrium and muscle layers of near-term rat uterine
tissues [42]. Further, treatment of murine uterine tissue with lipo-
polysaccharide (LPS) induced mRNA and protein expression of all
PLSCR family members with the exception of PLSCR4, which was
reduced [43]. PLSCR4 expression correlates with total number of
newborns, as well as number of pups born alive in a porcine
bead-chip investigation, and this suggests a role for PLSCR4 in uter-
ine functions [44]. Moreover, expression of PLSCR4 (and genes
involved in lipid/cholesterol metabolism) is down-regulated in
high-fat diet-receiving mice following treatment with Korean red
ginseng extract, implicating this PLSCR family member in obesity
[45]. PLSCR levels were also altered following induction of the
acute innate immune response (induced by LPS, zymosan, and tur-
pentine) in mice [46]; in cultured HepB3 hepatocytes (as well as
3T3-L1 adipocytes), PLSCR1 mRNA levels were increased following
treatment with inﬂammatory cytokines (tumor necrosis factor-a
(TNF-a), interleukins (IL-1b and IL-6), as well as interferon (IFN)-
c) [46]. PLSCR1 expression is also upregulated in response to
growth factors (i.e. epidermal growth factor (EGF) [47], stem cell
factor (SCF) [48], and granulocyte colony stimulating factor
(G-CSF) [48]) and by all-trans-retinoic acid (ATRA, a differentia-
tion-inducing agent) which is mediated by PKC-d activation in
acute promyelocytic leukemia (NB4) and HL60 cells [49]. In MCF-
7 breast cancer cells, PLSCR2 protein levels were down-regulated
following c-irradiation [50].
PLSCR1 was identiﬁed as one of the most potently induced
interferon-stimulated genes (ISGs) by differential oligonucleotide
array screening in the ﬁbrosarcoma HT1080 cell line in response
to Type I and II interferons (i.e. IFN-a, IFN-b, and IFN-c) [51]. The
PLSCR1 genomic sequence showed three possible IFN-regulated
binding sites within the ﬁrst 4 kb of 50 ﬂanking sequence, including
a single consensus interferon-stimulated response element (ISRE)
in its untranslated exon 1 that is essential for its induction
[12,52]. Transcriptional activation of PLSCR1 by IFN-a required
activation of Protein Kinase C (PKC)-d, (Jun Kinase) JNK, and Signal
Transducer and Activator of Transcription (STAT) 1 [53]. Recent
studies implicate Snail, a transcriptional regulator of epithelial-
mesenchymal transition (EMT), as a direct regulator of PLSCR1
transcription in IMR-32 and HEK-293 cell lines [54].
3.1.2. TMEM16 family
Inmice, TMEM16 familymembers display differential expression
depending on the developmental stage [34,55,56]. Notably,
TMEM16A and TMEM16F-TMEM16J have epithelial expression,
whereas TMEM16B-TMEM16E have neuronal-, skeletal-, and
muscle-speciﬁc expression [34,55,56]. Additionally, TMEM16A is
also expressed in Cajal interstitial cells in the smooth muscle of
gut; indeed, TMEM16A null mice lack movement of their gastroin-
testinal muscles [57]. Decreased expression of TMEM16A in these
cells has also been described in diabetic patientswho have gastropa-
resis [58]. TMEM16A is also expressed in airway smoothmuscle cells
implicating this protein in tracheal development and may also be
implicated in asthma development [59]. TMEM16B may play roles
in the sensory signalling as it is localized to olfactory sensory neu-
rons [60] and in photoreceptor synaptic terminals [61]. TMEM16F
is expressed in a number of cells, including hematopoietic cells
(involved in blood coagulation) [62] and osteoblasts (involved in
bone matrix production) [63]). Mechanisms underlying the regula-
tion of TMEM16 gene expression have yet to be investigated.
3.1.3. XKR family
Murine Xkr8mRNA is ubiquitously expressed (with high expres-
sion in testis), whereas murine XKR4 and XKR9 are tissue speciﬁc
[13,41]. In detail, murine XKR4 has the strongest expression in
brain (with weak expression in spleen, thymus, uterus, bloodvessels, and fetus), whereas XKR9 has the strongest expression in
the small intestine (with weak expression in pancreas, liver,
stomach and colon) [41]. Interestingly, methylation of CpG islands
in the XKR8 promoter region in cancer cell lines hindered mRNA
transcription of XKR8 and thus contributed to diminished phospho-
lipid scramblase activity [13]. Mechanisms underlying transcrip-
tional regulation of XKR expression remain unclear.
3.2. Post-translational modiﬁcations
Post-translational regulation of scramblases is, thus far, mainly
reported to occur via phosphorylation. These phosphorylation
events are regulated by several tyrosine kinases. EGF treatment
rapidly promotes PLSCR1 tyrosine phosphorylation (Y69/Y74)
mediated by c-Src [64]. c-Abl is another tyrosine kinase that can
contribute to tyrosine phosphorylation of PLSCR1 [65]. By contrast,
c-Src and c-Ablwere both unable to tyrosine phosphorylate PLSCR2,
PLSCR3, or PLSCR4 [64,65]. Additionally, activation of the IgE recep-
tor leads to tyrosine phosphorylation of PLSCR1 in rat mast cells
[66,67]; this PLSCR1 phosphorylation event ismediated in a cooper-
ative fashion by src family tyrosine kinasemembers, Lyn and Fyn, as
well as the FcRc chain [68]. In addition, PLSCR3 is threonine phos-
phorylated (T21) by PKC-d [69], and this phosphorylation event is
antagonized by heat shock protein 27 (HSP27), which disrupts the
physical interaction of PLSCR3 with PKC-d [70]). PLSCR3 phosphor-
ylation by PKC-d promotes cardiolipin translocation across the
mitochondrial membrane, thereby modulating apoptosis [71].
Although Frasch and colleagues reported that PLSCR1 could be
phosphorylated by PKC-d on threonine residues (Thr-161) [72],
phosphorylation of puriﬁed PLSCR1 from erythrocytes by PKC-d
was undetectable in an in vitro phosphorylation assay [49]. In
addition to phosphorylation, PLSCR family members also undergo
palmitoylation (described in detail in Section 3.3).
Based on in silico analyses, TMEM16F might be ubiquitinated at
Lys876/Lys888, whereas Asn329, Asn361, Asn493, Asn790 and
Asn802 have been predicted as potential glycosylation sites [73].
A potential sumoylation site has been identiﬁed in TMEM16A
and TMEM16F; however, its contribution to protein stability has
yet to be assessed [38]. Although putative phosphorylation sites
have been identiﬁed for TMEM16A and TMEM16B including PKC
sites [74], experimental validation is needed. With respect to
post-translational modiﬁcations of XKR8, its proteolytic processing
by caspase-3 leads to its activation [13,40]. Other XKR family
members (such as XKR4 and XKR9) also contain a caspase-cleavage
site at their C-termini [41]. Cleavage of these proteins is needed for
them to elicit functionality [13,41].
Collectively, further investigations into the post-translational
modiﬁcations of all of the phospholipid scramblase family
members would provide additional information with respect to
their mechanisms of regulation.
3.3. Subcellular localization
3.3.1. PLSCR family
PLSCR1 contains structural domains that might regulate its
subcellular localization: DNA binding domain (86–118 aa) [23],
cysteine-rich palmitoylation site (184CCCPCC189) [75,76], and an
atypical nuclear localization signal (NLS, 257–266 aa) [19,77].
Similar to other palmitoylated proteins, PLSCR1 localizes to the
plasma membrane speciﬁcally to the low density membrane
microdomain fraction (lipid rafts/caveolae). In support of this
observation, increased PLSCR1 and phospholipid scramblase activ-
ity during the maturation process of chondrocytes results in PS
enrichment in the outer leaﬂet of lipid-rich microdomains [78].
In addition, PLSCR colocalizes with EGFR in KB cells [47].
Interestingly, stimulation with EGF leads to internalization of
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in contrast to EGF receptor (EGFR) which is degraded in lysosomes,
PLSCR1 recycles back to the plasma membrane [47]. Moreover,
PLSCR1 co-localizes with the tyrosine kinases Lyn and Syk (down-
stream components of the IgE receptor signaling cascade) at the
lipid rafts of non-activated mast cells [79], and has been also found
in the lipid rafts of fMLP (formylated Met-Leu-Phe)-activated
neutrophils [80]. Interestingly, lipid rafts seem to be required for
the secretion of PLSCR1 into the extracellular matrix (ECM) in
HaCaT human keratinocyte cells, and this event is essential for
the interaction of PLSCR1 with the extracellular matrix protein 1
(ECM1) [81]. PLSCR1 is also found in other sites including the Golgi
and endosomal compartments [82,83].
The plasma membrane localization of PLSCR1 can be disrupted
by cellular treatment with 2-bromopalmitate (a general inhibitor
of palmitoylation) or via mutagenesis of the palmitoylation sites
in speciﬁc cell types [75] leading to its nuclear localization. Nuclear
localization of PLSCR1 can also be induced by IFN treatment of cer-
tain cell lines (i.e. HEY1B and SVT2 ﬁbroblasts) [75]. Nuclear
import of PLSCR1 requires its atypical NLS (257GKISKHWTGI266,
257–266 aa), and the activity of the importin a/b nuclear receptor
pathway [19,20]. In the nuclear compartment, PLSCR1 regulates
the transcription of IP3R [23] and may contribute to DNA replica-
tion via its physical interaction with topoisomerase [22]. Nuclear
PLSCR1 is involved in the production of mature neutrophils from
myeloid progenitors following exposure to G-CSF [21], although
the underlying mechanism is unclear. In addition, PLSCR1 regulates
angiogenin-enhanced rRNA transcription in the nucleus [24].
PLSCR4 is also localized at the plasma membrane [84], whereas
PLSCR3 is enriched in the mitochondrial membrane [85]. PLSCR3
has been experimentally shown to be palmitoylated using 3H-pal-
mitate labelling [85]. For example, mutagenesis of the cysteine
residues of PLSCR3 critical for its palmitoylation led to its redistri-
bution to the nuclear compartment [85]. Furthermore, secretion of
PLSCR3 in exosomes was inhibited by 2-bromopalmitate [86]. NLS
signals are also found in PLSCR2, PLSCR3, and PLSCR4. PLSCR2 is
predominantly nuclear localized when stably expressed in Chinese
hamster ovary K1 cell line [87], although its nuclear function
remains to be investigated. Mutation of the PLSCR4 minimal
nuclear localization sequence (273GSIIRKWN280) disrupts its locali-
zation to the nuclear compartment [25].
3.3.2. TMEM16 family
Murine TMEM16F was found to localize to the plasma mem-
brane, when expressed as a monomeric red ﬂuorescent protein
(mRFP) conjugate in 293T cells [38]. However, another indepen-
dent report presented evidence for a cytoplasmic localization of
TMEM16F [88]. Following tagging with C-terminal GFP, several
other TMEM16 family members were reported not to reach the
plasma membrane, but rather were retained intracellularly in
HEK293, CHO, and COS-7 cells [88]. In detail, TMEM16A has been
found to localize to the plasma membrane, whereas GFP-conju-
gated TMEM16C-TMEM16G and TMEM16J localized in the
endoplasmic reticulum; this differential localization pattern may
associate with the differential ability of these proteins to generate
calcium-activated Cl currents [88]. As protein overexpression
(and tagging proteins with ﬂuorescent proteins) might result in
artefacts, investigation of the endogenous expression of these
family members is still needed. Thus far, the endogenous localiza-
tion of TMEM16G was assessed in human prostate tissue, where
TMEM16G was found to be enriched in its epithelium, and local-
ized mainly to intracellular regions [88].
3.3.3. XKR family
According to Genecards (http://www.genecards.org), XKR8 has
been suggested to be predominantly localized at the plasmamembrane, and this would correspond to its role as a phospholipid
scramblase mediating PS externalization in apoptotic cells [41].
Indeed, when expressed as GFP-fusion proteins, murine XKR-fam-
ily members (with the exception of XKR2) were found to localize to
the plasma membrane [41]. However, only XKR4, XKR8, and XKR9
promote PS externalization in response to apoptotic stimuli [41].
Truncated GFP-fusion proteins of XKR8 and XKR9 (which lack the
C-terminal caspase-cleavage site) were mislocalized to the
endoplasmic reticulum. Thus, the dibasic/diaromatic amino acids
that are located at the C-terminal of the caspase cleavage site
may contain an ER export signal [41]. By contrast, cleaved XKR4
was not mistargeted suggesting that the C-terminal segment (after
the caspase cleavage site) is not essential for its appropriate
subcellular localization [41].
3.4. Molecular functions of phospholipid scramblases
3.4.1. PLSCR family
With regards to the protein interactome for PLSCR family
members, several targets have thus far been identiﬁed which
may implicate PLSCR in regulating their function. For example,
PLSCR1 interacts with toll-like receptor 9 (TLR9) in endosomal
compartments to regulate TLR9-mediated production of IFN-a
[83]. TLRs contribute to innate immune system cellular responses
by functioning as receptors recognizing foreign and pathogenic
nucleic acids/proteins that enter cells [89–92]. Although the
detailed mechanism by which PLSCR1 modulates the TLR signaling
and innate immune responses is presently unclear, these observa-
tions provide a link between PLSCR1 regulation and innate
immune responses. PLSCR1 has also been shown to interact with
EGFR and Shc-A, an adaptor molecule in EGF stimulated A431 epi-
dermoid carcinoma cells [64]. PLSCR1 interaction with Shc-A
requires Src-mediated phosphorylation on tyrosines 69 and 74 in
the N-terminal region of PLSCR1 [64]. In T cells, PLSCR1 and PLSCR4
interact with plasma membrane localized CD4 receptor which is
regulated by the presence of the secretory leukocyte protease
inhibitor (SLPI), which has anti-viral activity against human immu-
nodeﬁciency virus 1 (HIV-1) [84]. These results suggest a potential
role of PLSCR1 in receptor-mediated signaling pathways and recep-
tor internalization. In neutrophils, PLSCR1 was shown to interact
with Proteinase 3 (PR3), which is a target of autoantibodies in
Wegener granulomatosis [93]. In SH-SY5Y human neuroblastoma
cells, PLSCR1 interacts with b-secretase APP cleaving enzyme
(BACE), a membrane proteinase enzyme that regulates the produc-
tion of amyloid b-peptide molecules (a characteristic feature of
Alzheimer’s disease) in the Golgi and endosomal compartments
[82]. Thus, PLSCR1 may regulate the intracellular distribution of
BACE and potentially implicates a role for PLSCR1 in Alzheimer’s
disease pathophysiology. In myeloid cells, PLSCR1 binds to onzin,
a negative transcriptional regulatory target of c-Myc which regu-
lates cell proliferation [94]. This ﬁnding potentially implicates
PLSCR1 in cancer cell survival and proliferation. Furthermore,
PLSCR1 interacts with receptors expressed in lymphoid tissues
(RELT), and this interaction leads to phosphorylation of PLSCR1
by OSR1, an oxidative stress response kinase protein [95]; this
ﬁnding may implicate PLSCR1 in oxidative stress response path-
ways. As described earlier, PLSCR1 is secreted into the ECM via a
lipid raft-dependent pathway thus promoting its interaction with
ECM1; this suggests a potential role for PLSCR1 in epidermal
differentiation mediated by ECM1 [81]. In addition, PLSCR1 is an
angiogenin-interacting protein in the nuclear compartment to
modulate rRNA transcription [24].
Since PLSCR1 is highly inducible by IFN-a, IFN-b, and IFN-c [51],
the role of PLSCR1 in mediating antiviral activities has recently
come under much investigation. Cells with reduced expression of
PLSCR1 (via siRNA or ﬁbroblasts from PLSCR1/ knockout mice)
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encephalomyocarditis (EMCV) viruses [96]. In HepG2 and Huh7
cell lines (as well as in mice), expression of PLSCR1 affects Hepati-
tis B virus (HBV) replication (reduction of viral proteins, RNAs, and
DNA replicative intermediates) [97]. Although PLSCR1 was upreg-
ulated via IFN-a and IFN-c to oppose hepatitis C virus (HCV) repli-
cation [98], PLSCR1 was also reported to promote viral entry of
HCV [99]. In HEK293T and Huh7.5.1 cells, PLSCR1 interacts with
the E1 and E1 HCV envelope proteins as well as other entry factors
(i.e. OCLN) to coordinate HCV infection [99]. Further studies of
PLSCR1 expression and its effects on viral infection, however, con-
tinue to support the role of PLSCR1 in mediating antiviral activity.
For instance, PLSCR1 interacts with and regulates the transactiva-
tion of HTLV-1 tax, a protein associated with the transcription of
the Human T-cell Leukemia Virus type-1 provirus [100]. In a sim-
ilar study, PLSCR1 was found to interact with HIV-1 Tat, a protein
essential to the transcription of the Human Immunodeﬁciency
Virus type-1 long terminal repeat (LTR) [101]. Collectively, these
studies implicate PLSCR1 in viral responses in which it can both
assist in the viral infection and inhibit viral replication and propa-
gation. Interestingly, IFN-a stimulates expression of PLSCR1 in
order to protect cells from staphylococcal a-toxin produced during
S. aureus infection [102,103]. Knockdown of PLSCR1 by shRNA sup-
ports a protective role for PLSCR1 following a-toxin exposure
[102,103].
Although there is controversy surrounding the role of PLSCR
family members in mediating PS externalization, there is evidence
demonstrating PLSCR contribution to this function. For example,
scrm-1 (C. elegans ortholog of human PLSCR1) mediates PS exter-
nalization in apoptotic cells [16]. In addition to PLSCR1-mediated
apoptotic events, PLSCR3 is another PLSCR family member that
contributes to apoptosis induced by UV and tBid [104]. The PLSCR3
isoform markedly increases TNF-related apoptosis-inducing ligand
(TRAIL)-induced mitochondrial apoptotic pathway [105]. During
PKC-d -induced apoptosis, PLSCR3 is phosphorylated at Thr-161
[69,106]. The phosphorylation of PLSCR3 by PKC-d is also an early
event in apoptotic cells treated with N-benzyladriamycin-14-val-
erate (AD198) [107].
Recent studies on hybrid mapping of yeast and human interac-
tion networks identiﬁed PLSCR1 as one of the interaction partners
of ATG12, an ubiquitin-like protein that helps in the elongation
step of autophagosome formation [108]. These ﬁndings suggest a
potentially important role for PLSCR1 in the process of autophago-
some formation. In addition, LC3-II (via western analysis) and GFP-
LC3 punctae (via immunoﬂuorescence) levels were altered
following PLSCR1 knockdown in ovarian cancer cells treated with
arsenic trioxide [109]. However, the exact mechanism by which
PLSCR1 contributes to autophagy requires further investigation.
PLSCR3 is also implicated in regulating pro-death autophagy; in
particular, PLSCR3 is involved in externalizing cardiolipin, an event
important in targeting the damaged mitochondria to autophago-
somes/lysosomes during the process of mitophagy (a type of
autophagy that speciﬁcally targets the damaged mitochondria for
degradation) [71].
3.4.2. TMEM16 family
Ist2, a yeast homolog of TMEM16 ion channels, has been
described as an endoplasmic reticulum-plasma membrane (ER-
PM) tethering proteins and is localized at these junctional sites in
yeast cells [110]. Deletion of Ist2 (aswell as other tethering proteins
such as tricalbins and Scs2/Scs22) promotes detachment of the ER
from the PM [110]. The ER-PM attachment sites are important in
calcium and PI signaling at the plasmamembrane [110]. In addition
to its suggested phospholipid scramblase activity, TMEM16F is a
critical factor in the outwardly rectifying Cl channel (ORCC)
[111], and may play a role in promoting chloride currents inresponse to FasL-activation in Jurkat cells [112] and staurospaurine
mediated ORCC in epithelial cells [111]. Indeed, this activity is
absent in TMEM16F/ cells [113]. There also are conﬂicting reports
of TMEM16F as a Cl channel [31,113,114]. Nonetheless, mutation
of Q559 to a lysine in TMEM16F increased its Cl channel activity
[113]. Mutation at E670Q in TMEM16F downregulated its plasma
membrane expression while mutation at E667Q markedly
decreased the calcium-sensitivity of its channel activity in the
absence of any changes in plasmamembrane localization [113,115].
With respect to TMEM16 family members, TMEM16A forms
both homo- and heterodimers with TMEM16B but not TMEM16F
[74,116]. The cellular role for formation of these oligomers remains
unclear. A proteomics approach was implemented to identify
TMEM16A binding proteins; 73 proteins were increased in their
screen by >3-fold including SNARE proteins as well as the ezrin–
radixin–moesin (ERM) scaffolding complex [74,116]. Downregula-
tion of these targets via knockdown methodology could modulate
Cl channel activity of TMEM16A [74,116]. In addition, the IP3R1
(inositol 1,4,5-triphosphate receptor 1) was identiﬁed to bind to
TMEM16A [74,117].
3.4.3. XKR family
Cleaved XKR4 (with highest expression in brain) may be
involved in functions of the synapse, axons, and dendrites by
externalization of PS which may lead to remodelling of the ‘‘neural
network’’ [41]. In small intestinal epithelial cells, cleaved XKR9
may promote migration via the process of ‘‘shedding’’ in which
PS externalization may be involved [41].4. PLSCR, TMEM16, and XKR-associated scramblase activities
When erythrocyte-puriﬁed PLSCR1 was reconstituted into lipo-
somes, rapid bidirectional movement occurred in a similar manner
to that in plasma membranes following Ca+2 mobilization [10].
Similar results were obtained with puriﬁed recombinant PLSCR1
protein fused to maltose-binding protein (MBP) reconstituted in
liposomes [11] as well as with PLSCR1 fused to green ﬂuorescent
protein (GFP) expressed in Burkitt’s lymphoma Raji cells treated
with A23187, a calcium ionophore [118]. The calcium binding site
in PLSCR1 (273–284 aa) is required for mediating calcium-induced
phospholipid scrambling activity [119].
With respect to other PLSCR family members, mutations in the
calcium-binding site of PLSCR4 markedly reduces its Ca+2 and
Mg+2-induced scramblase activity [120]. PLSCR3, which is localized
in mitochondrial membranes, externalizes cardiolipin from the
inner to the outer mitochondrial membrane [121]. By contrast,
PLSCR2 lacks scramblase activity; this was attributed to the
absence of the proline-rich N-terminal region that is present in
the other PLSCR family members [122]. Indeed, when fused to
the proline-rich domain of PLSCR1, PLSCR2 is capable of calcium-
dependent scrambling activity [122]. Although the above studies
implicate PLSCRs in the redistribution of phospholipids between
membrane leaﬂets, there may be other factors contributing to PS
externalization in response to apoptotic stimuli [123]. PLSCR1
expression does not always correlate with PS exposure during
apoptosis [123]. Indeed, PLSCR1/ mice were fully proﬁcient in
mediating scramblase activity (with no apparent defect in coagula-
tion) suggesting that PLSCR1 may not be essential for mediating PS
exposure [48]. As PLSCR3 and PLSCR4 also seem to contribute to
scrambling activity [120,121], these isoforms may overcome the
loss of PLSCR1 by eliciting redundant scramblase activity that
enables PS externalization in PLSCR1/ mice. However, PLSCR1/
and PLSCR3/ double knockout mice still retain scramblase activ-
ity [124]. In addition, PLSCR1 protein was normal in patients with
Scott syndrome, a severe bleeding disorder that is characterized by
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red cells, and lymphocytes resulting in a defective blood coagula-
tion process [126] that is now attributed to TMEM16F loss of func-
tion mutations [14]. Another factor that results in PS exposure is
wah-1 (apoptosis inducing factor) which interacts with scrm-1 to
promote PS exposure [15]; phospholipid scramblase activity is ele-
vated when these two proteins interact [15]. Interestingly, treat-
ment with an anti-phospholipid scramblase 1 antibody (NP1)
increased apoptosis in colorectal cancer cells [127].
Recently, TMEM16F, a calcium-dependent chloride channel was
identiﬁed as the factor mutated in Scott syndrome platelets that
leads to scramblase deﬁciency [14]. Further, TMEM16F knockout
mice (TMEM16F/) displayed excessive bleeding defects and
defective lipid scrambling activity in platelets [113], whereas
another TMEM16F-knockout model had severe bone abnormalities
with defective phospholipid scrambling in their osteoblasts in the
absence of excessive bleeding defects (i.e. which may be expected
in females after giving birth) [63]. Even with this family of proteins,
there is controversy regarding whether TMEM16F elicits
scramblase activity or is a membrane channel regulating scramb-
lase activity. In some studies TMEM16F overexpression failed to
promote calcium-dependent PS externalization, whereas other
reports support a role for TMEM16F as a scramblase
[14,62,113,128]. Therefore, it has been suggested that TMEM16F
may function as a channel which regulates a scramblase protein
[14,62,113,128]. Recently, this was addressed using a biochemi-
cally pure protein from A. fumigatus (afTMEM16, a calcium-gate
channel and a calcium-dependent scramblase) whose scramblase
activity was assessed directly in a liposomal reconstitution system
[35]. Compared to TMEM16A and Ist2p (a Saccharomyces cerevisiae
protein ortholog involved in salt tolerance [129]), only afTMEM16
directly exerted scramblase activity [35]. Some other TMEM family
members including TMEM16C, TMEM16D, TMEM16F, TMEM16G,
and TMEM16J are capable of scrambling lipids with some differ-
ences in their speciﬁcity [62]. However, TMEM16A and TMEM16B
are Cl anion channels and are not associated with scramblase
activity [62]. Mutational study of the pore region in both
TMEM16A and TMEM16F (between the 5th and 6th transmem-
brane region) is critical for these proteins to elicit Cl channel
and phospholipid scramblase activity, respectively [38]. Domain
swapping studies were performed in which speciﬁc regions
between TMEM16A and TMEM16F were exchanged leading to
the elimination of Cl channel and scramblase activity, respec-
tively [38]. The active sites therefore are likely to be quite differ-
ent; this conclusion was also obtained by inhibitor studies (drugs
targeting TMEM16A but not TMEM16F and vice versa) [38]. For
example, tannic acid and epigallocatechin gallate (EGCG) have
antithrombotic activities and inhibit TMEM16F scramblase activ-
ity. Both molecules are dependent on calcium although no EF hand
has been identiﬁed [38].
As TMEM16F/ cells exhibit normal levels of PS externalization
in response to apoptotic stimuli, other factors are probably
responsible for PS externalization under apoptotic conditions.
Interestingly, XKR8, when activated by caspase-3 (an important
mediator in the apoptotic signalling cascade), was shown to be
responsible for externalizing PS in response to apoptotic stimuli;
this was demonstrated using XKR8/ murine and human cancer
cells treated with XKR8 siRNA [13,40]. XKR8-deﬁcient immortal-
ized fetal thymocytes (IFETs) and murine embryonic ﬁbroblasts
(MEFs) (both cell types have low to undetectable levels of XKR4
and XKR9) did not externalize PS in response to apoptotic stimuli
[41]. Additionally, Jurkat and Namalwa cells, which can both exter-
nalize PS, have high levels of XKR8 and XKR9 (but lack XKR4),
whereas PLB-985 and Raji do not externalize PS and completely
lack detectable expression of any XKR family members [41]. When
murine XKR8/ IFETs were reconstituted with XKR8 and XKR9,they regained the ability to externalize PS in response to apoptotic
stimuli [41]. In addition, UV-irradiated PLB-985 cells overexpress-
ing XKR8 elicited a similar PS response [41]. Interestingly, although
C-terminal deletion variants of XKR family members, speciﬁcally
XKR8 (at Asp-354) and XKR9 (at Asp-357), prevented PS exposure
in apoptotic cells, apoptotic cells expressing truncated XKR4 (at
Asp-564) still externalized PS in response to staurospaurine, an
apoptotic stimuli [41]. From extensive mutational analyses, E141
and S184 seem to be required for the ability of XKR8 and CED-8
to externalize PS in response to apoptotic stimuli [41]. However,
when CED-8 was expressed in murine cells, they failed to promote
PS externalization, suggesting that another factor mediates
scramblase activity in C. elegans [41]. Thus, it is presently unclear
whether XKR4, XKR8, and XKR9 are direct mediators of
phospholipid scramblase activity or work collaboratively with
another protein to regulate this activity [41]. An in vitro liposomal
reconstitution assay has yet to be performed to directly assess
phospholipid scramblase activity of XKR family members.
5. Phospholipid scramblases in human diseases
5.1. PLSCR
5.1.1. Autoimmunity and inﬂammation
Approximately 10% of patients with systemic lupus erythema-
tosus (SLE) exhibit an unusual increase in blood coagulation [18];
in the monocytes of these patients, the expression level of the
full-length PLSCR1, as well as of the three PLSCR1 splice variants
was found to be increased, along with elevated PS externalization
[18]. Although the signiﬁcance of these ﬁndings remains to be
investigated, this observation implicates PLSCR1 in the pathophys-
iology of SLE. It is interesting to note that all three splice variants
had an intact calcium binding (EF-hand-like) domain, which con-
tributes to PLSCR1 scramblase activity [18]. In addition, PLSCR1
expression was elevated in monocytes isolated from patients with
anti-phospholipid syndrome [130]. In this autoimmune disease,
the recognition of externalized PS by anti-phospholipid antibodies
leads to damaged cell membranes and thus increased blood clots
and uncontrolled thrombin production [130].
5.1.2. Cancer development
PLSCR1 mRNA expression was markedly increased upon treat-
ment with ATRA, a chemotherapeutic agent used in treatment of
acute promyelocytic leukemia (APL) [49]. Further, reduced PLSCR1
expression signiﬁcantly suppressed the differentiation of APL cells
implicating PLSCR1 as an anti-leukemic molecule [49,131]. Studies
in acute myelogenous leukemia (AML) patients revealed that ele-
vated PLSCR1 mRNA expression correlated with increased survival
[132]. In addition, PLSCR1 expression and its localization were
altered when AML cells were treated with wogonoside, a Chinese
herbal medicine used to treat blood-related malignancies [133].
PLSCR1 expression could also inhibit U937 myeloid leukemia cell
proliferation by modulating the expression of pro-survival and
anti-apoptotic proteins [133]. These above-described observations
implicate PLSCR1 as a tumor suppressor in leukemia development.
A similar function is attributed to PLSCR1 in ovarian cancer cells
wherein murine xenograft (HEY1B ovarian cancer cells expressing
PLSCR1) growth suppressed tumor development, although there
was no observed functional defect observed in vitro [134].
Nevertheless, accumulating evidence also supports PLSCR1 as
an oncogenic molecule in ovarian [109], colorectal [135,136], and
metastatic liver cancers [137]. PLSCR1 was not highly elevated in
various colorectal cancer (CRC) patient tissues but antibody or siR-
NA mediated downregulation of PLSCR1 in colorectal and liver
cancers dramatically reduced in vivo tumorigenesis [135–137].
Although PLSCR1 suppresses tumor development in a mouse
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cells (and cancer specimens based on TCGA analyses [109]) in com-
parison to normal T80 ovarian cells [109]. As discussed earlier,
Snail plays an important role in tumor progression and is upregu-
lated in several cancers [138]. Since Snail modulates PLSCR1
expression [54], this may be one mechanism involved in the tran-
scriptional regulation of PLSCR1 in cancer.
5.1.3. Lipid-related diseases
Overexpression of PLSCR3 through mRNA upregulation leads to
increased cardiolipin production, primarily via upregulation of
cardiolipin synthase activity (as opposed to phosphatidylglycerol-
phosphate synthase) [121]. Furthermore, there was a notable
increase in ER monolysocardiolipin acyltransferase activity
(including its mRNA levels) in the absence of changes in the decar-
boxylation of PS to PE in the mitochondria [121]. Interestingly,
PLSCR3 is expressed to a high level in fat and muscle [124]. Knock-
out PLSCR3/ mice have a marked accumulation of abdominal fat;
they also were intolerant for glucose and resistant to insulin with
abnormal amounts of lipids in their blood (cholesterol, triacylgly-
cerides, fatty acids, and leptin) [124]. Studies using isolated
adipocytes and macrophages from the bone-marrow of PLSCR3/
knockout mice indicated an abnormality in the levels of neutral
lipids and resistance to insulin presentation [124]. Metabolic
proﬁling in PLSCR3/ (as well as PLSCR1//PLSCR3/ double
knockout) mice led to the identiﬁcation of 19 metabolites that
were regulated by these phospholipid scramblases, speciﬁcally
the upregulation of pro-inﬂammatory lipids and genes involved
in lipid metabolism in adipose tissues [124]. These observations
suggest that the loss of PLSCR1 may lead to the development of
lipid-related diseases.
5.2. TMEM16 family
Aside from mutations in Scott syndrome patients [14,37],
polymorphisms within TMEM16F have been associated with
inﬂammatory bowel disease, a complication of the autoimmune
disease ankylosing spondylitis (observed in a Taiwanese popula-
tion) [139]. The mechanism by which TMEM16F contributes to
the development of this disease remains unclear and requires fur-
ther investigation. Although TMEM16K mutations have been
shown to lead to adult-onset cerebellar ataxia and coenzyme Q10
deﬁciency in muscle [140], TMEM16E missense mutations occur in
patients with gnathodiaphyseal dysplasia (a disease characterized
by skeletal defects) [141,142], and TMEM16C mutations are linked
to autosomal dominant disease, craniocervical dystonia [143], the
mechanisms by which these occur and their contribution to dis-
ease progression remains unclear.
Dysregulated expression of TMEM16 family members in cancer
has also been described. For instance, TMEM16A (the original
identiﬁed member of this large family of transmembrane proteins),
is ampliﬁed at chromosome 11q13 locus [73,144] in a subset of
cancers [88,145,146] while TMEM16G is dysregulated in prostate
cancer [147]. It is presently unclear whether these changes are a
cause or an effect of cancer initiation or evolution. Interestingly,
from an exon-array analysis, the splicing pattern of TMEM16F is
altered in metastatic breast cancers [148]. The functional conse-
quences of the expressed altered splice variants of TMEM16F
require further investigation. Interestingly, TMEM16F (and
TMEM16A) have been shown to modulate cellular motility and
thus, may be involved in promoting cancer aggressiveness [149].
5.3. XKR family
XKR mutations are responsible for the McLeod syndrome, an
X-linked genetic disorder characterized by muscular dystrophy,cardiomyopathy, with multiple other defects including those of
haematological origin [150]. However, the mechanism by which
XKR leads to these functional defects remains unclear. Polymor-
phisms in the XKR4 gene seem to be associated with the effect of
the dopamine iloperidone antagonist (used in schizophrenia treat-
ment) [151]; this ﬁnding may provide important information with
respect to patient response to this drug. Meanwhile, a polymor-
phism in XKR6was correlatedwith lupus nephritis which is a defect
in patients with SLE [152] which is characterized by the immune
system attacking the cells and tissues of the host, thereby leading
to inﬂammation in various organs of the body. However, the role
of XKR6 in the development of this disease yet remains unclear.
With respect to cancer initiation and evolution, XKR members
have thus far only been studied in cancer cell lines in terms of their
ability to externalize PS under apoptotic conditions [13]. Whether
XKR family members are dysregulated in speciﬁc cancers has yet to
be investigated. Furthermore, it is unclear whether the ability of
XKR to modulate PS externalization can alter cancer development
or response to chemotherapeutic agents.
6. Conclusions and perspectives
PLSCR, TMEM16, and XKR family members have been impli-
cated in the plasma membrane externalization of PS. The process
of phospholipid scrambling between the two leaﬂets of plasma
membrane is critical in cellular events such as blood coagulation
and apoptosis. Earlier studies have implicated phospholipid
scramblase (PLSCR) family members in this process. However, later
studies in Scott Syndrome patients revealed that PLSCR members
may not be responsible for the PS externalization during blood
coagulation. This activity has now been ascribed to TMEM16F
(and some additional family members). Furthermore, since scram-
bling activity remained unaltered in knockout mice with a deletion
in PLSCR1 (and/or PLSCR3), there may be redundant function for
various members of the PLSCR family. It remains to be investigated
whether combinatorial deletion in mice of all known PLSCR
members would alter scrambling activity. Nonetheless, XKR8
(and other XKR family members) has recently been implicated in
PS externalization in response to apoptotic stimuli. In addition to
externalization of PS, phospholipid scramblases elicit a number
of other diverse and important cellular functions. Speciﬁcally, they
play roles in autoimmunity, protection against viruses and bacte-
ria, cell death (apoptosis and autophagy), lipid metabolism, genetic
diseases, and cancer.
Although PKC-d, JNK, and STAT1 signalling molecules as well as
the ISRE element present in the untranslated exon 1 of PLSCR1
contribute to the transcriptional induction of PLSCR1, the complete
mechanism of its transcriptional regulation remains to be
investigated. Thus far, the only transcriptional regulatory molecule
identiﬁed to regulate PLSCR1 is Snail [54]. Further investigations
are required to identify transcriptional regulators of PLSCR1 and
other phospholipid scramblase family members. Further, it is cur-
rently unknown how TMEM16 and XKR family members are trans-
criptionally regulated. Although there are multiple links between
PLSCR1 and autophagy, the detailed underlying mechanism of
how PLSCR1 contributes to this process remains unclear. As XKR
family members can modulate the apoptotic pathway, it is possible
that this molecule can alter autophagic ﬂux; thus, studies can be
conducted to investigate this possibility. PLSCR1 is described to
elicit both tumour suppressive and oncogenic roles in cancer
development, but further investigations are needed to clarify the
role of this molecule (as well as TMEM16 and XKR family mem-
bers) in the pathogenesis of cancer. From TCGA data, PLSCR1 is
altered in ovarian cancer patients and these alterations are highly
correlated with that of SnoN/SkiL, an oncogene that is overexpres-
sed at 3q26.2 in ovarian and other epithelial cancers [153]. Another
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endogenous phospholipid scramblase in cell lines as well as in can-
cer specimens; as described earlier, the localization of PLSCR1
plays an important role in its functions. For example, although
PLSCR1 is overexpressed in colorectal cancer tissue specimens
[136], its subcellular localization was not assessed. Further studies
are needed to further elucidate the role of PLSCR1 as well as other
phospholipid scramblase family members (TMEM16 and XKR) in
ovarian and other cancers.
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